Amicogen (A092040) 주식 개요아미코젠은 한국과 해외에서 산업 생명공학 회사로 운영되고 있습니다. 자세히 보기A092040 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성2/6배당0/6위험 분석지난 5년간 매년 수익이 46.3% 감소했습니다.지난 3개월 동안 주가 변동성이 KR 시장과 비교해 높았습니다.지난 1년 동안 주주가 희석되었습니다.의미 있는 시가총액이 없습니다(₩132B)모든 위험 점검 보기A092040 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩1.71k2.6% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-53b174b2016201920222025202620282031Revenue ₩40.6bEarnings ₩7.4bAdvancedSet Fair ValueView all narrativesAmicogen, Inc. 경쟁사GeneOne Life ScienceSymbol: KOSE:A011000Market cap: ₩148.2bCell BiotechSymbol: KOSDAQ:A049960Market cap: ₩120.8biNtRON BiotechnologySymbol: KOSDAQ:A048530Market cap: ₩97.1bTegoScienceSymbol: KOSDAQ:A191420Market cap: ₩85.4b가격 이력 및 성과Amicogen 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩1,710.0052주 최고가₩4,980.0052주 최저가₩1,160.00베타0.211개월 변동-11.99%3개월 변동7.01%1년 변동-42.52%3년 변동-82.23%5년 변동-90.59%IPO 이후 변동-76.21%최근 뉴스 및 업데이트공시 • Mar 11Amicogen, Inc., Annual General Meeting, Mar 31, 2026Amicogen, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South KoreaNew Risk • Feb 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (₩87.7b market cap, or US$61.5m).New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩69.6b market cap, or US$48.2m).공시 • Feb 10Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion.Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 1164분석 기사 • Dec 22Investors Don't See Light At End Of Amicogen, Inc.'s (KOSDAQ:092040) Tunnel And Push Stock Down 33%Unfortunately for some shareholders, the Amicogen, Inc. ( KOSDAQ:092040 ) share price has dived 33% in the last thirty...New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 52% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩108.0b market cap, or US$73.0m).더 많은 업데이트 보기Recent updates공시 • Mar 11Amicogen, Inc., Annual General Meeting, Mar 31, 2026Amicogen, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South KoreaNew Risk • Feb 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (₩87.7b market cap, or US$61.5m).New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩69.6b market cap, or US$48.2m).공시 • Feb 10Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion.Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 1164분석 기사 • Dec 22Investors Don't See Light At End Of Amicogen, Inc.'s (KOSDAQ:092040) Tunnel And Push Stock Down 33%Unfortunately for some shareholders, the Amicogen, Inc. ( KOSDAQ:092040 ) share price has dived 33% in the last thirty...New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 52% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩108.0b market cap, or US$73.0m).공시 • Dec 20Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion.Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 2010New Risk • Dec 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩143.8b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩143.8b market cap, or US$97.9m).New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩44b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years.분석 기사 • Sep 08The Market Doesn't Like What It Sees From Amicogen, Inc.'s (KOSDAQ:092040) Revenues YetWith a price-to-sales (or "P/S") ratio of 1.8x Amicogen, Inc. ( KOSDAQ:092040 ) may be sending very bullish signals at...공시 • Aug 12Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.On August 11, 2025, Amicogen, Inc. closed the transaction.New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 46% per year over the past 5 years.분석 기사 • May 23Amicogen, Inc.'s (KOSDAQ:092040) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.3x Amicogen, Inc. ( KOSDAQ:092040 ) is definitely a...Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.공시 • Mar 12Amicogen, Inc., Annual General Meeting, Mar 27, 2025Amicogen, Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea분석 기사 • Feb 17Is Amicogen (KOSDAQ:092040) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Jan 08Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 35%Amicogen, Inc. ( KOSDAQ:092040 ) shareholders are no doubt pleased to see that the share price has bounced 35% in the...New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).공시 • Dec 12An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion.An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion on December 10, 2024. After completion of this ransaction, Amicogen, Inc. will hold 14.36% stake in Amicogen (China) Biopharm. Amicogen (China) Biopharm reported total assets of KRW 210.359 billion, total debt of KRW 95.656 billion, sales of KRW 84.911 billion and net income of KRW 8.074 billion as at September 30, 2024. The expected completion of the transaction is December 30, 2024.New Risk • Dec 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 3.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (40% increase in shares outstanding).공시 • Nov 23Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040).Enzynomics Co., Ltd. agreed to acquire 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 5.6 billion on November 15, 2024. A cash consideration of KRW 5.6 billion will be paid by Enzynomics for 2,360,714 shares. For the period ending December 31, 2023, SKINMED Co., Ltd. reported total revenue of KRW 6.07 billion and net loss of KRW 1.04 billion. As of December 31, 2023, SKINMED Co., Ltd. reported total debt of KRW 4.96 billion, total assets of KRW 11.22 billion and total common equity of KRW 6.26 billion. Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) on November 19, 2024.분석 기사 • Nov 11Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share PriceAmicogen, Inc.'s ( KOSDAQ:092040 ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a strong buy right...공시 • Oct 30+ 1 more updateAmicogen, Inc. announced that it has received KRW 4 billion in funding from Kiwoom Securities Co., Ltd.On October 29, 2024 Amicogen, Inc. closed the transaction.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).분석 기사 • Jun 27Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% PoundingTo the annoyance of some shareholders, Amicogen, Inc. ( KOSDAQ:092040 ) shares are down a considerable 27% in the last...분석 기사 • Jun 19Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Mar 21Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%Amicogen, Inc. ( KOSDAQ:092040 ) shares have had a really impressive month, gaining 39% after a shaky period...New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).공시 • Jul 19+ 1 more updateAmicogen, Inc. announced that it expects to receive KRW 40 billion in fundingAmicogen, Inc. announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 40,000,000,000 on July 18, 2022. The bonds will mature on July 20, 2027. The bonds are convertible into 1,622,520 common shares at a price of KRW 24,653 per share. The conversion period is from July 20, 2023 to June 20, 2027. The payment date is July 20, 2022. The transaction has been approved by the board of directors.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩24,850, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total loss to shareholders of 34% over the past three years.공시 • Sep 03Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AGOn September 2, 2021, Amicogen, Inc. closed the transaction.공시 • Jul 23Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion.Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion on July 21, 2021. Under the term, Amicogen will acquire 2.45 million shares of BIFIDO at KRW 24,500 per shares. Amicogen will pay 20% of the consideration amounting to KRW 12.02 billion on July 21, 2021 as the down payment or first payment, second payment or the interim payment which is 30% of the consideration amounting to KRW 18.04 billion will be paid on August 20, 2021 and the balance which is 50% of the consideration amounting to KRW 30.06 billion will be paid on October 20, 2021. Post completion, Amicogen will hold 30% stake in BIFIDO. The transaction was resolved by the board of directors of Amicogen on July 21, 2021. The transaction is expected to close on October 21, 2021.공시 • Jul 15Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AGAmicogen, Inc. announced a private placement of 532,198 shares at a price of KRW 41,850 per share for gross proceeds of KRW 22,272,486,300 on July 14, 2021. The transaction will include participation from Lysando AG. The transaction is expected to close on August 20, 2021. The securities to be issued will have a hold period of 1 year. The transaction was approved by the board of directors of the company. The company will received funding through third party allocation.공시 • Jul 01Amicogen, Inc. announced that it has received KRW 50 billion in fundingOn June 29, 2021, Amicogen, Inc. closed the transaction.공시 • Jun 24Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding from Samsung Securities Co., Ltd. and other investorsAmicogen, Inc. (KOSDAQ:A092040) announced a private placement of series 1 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 50,000,000,000 on June 23, 2021. The transaction will include participation from Samsung Securities Co., Ltd. (KOSE:A016360) for KRW 46,000,000,000, and Small and Medium Business Banks for the rest. The bonds will mature on June 28, 2026. The bonds are convertible into 1,203,311 common shares at a price of KRW 41,552 per share. The conversion period is from June 29, 2022 to May 29, 2026. The payment date is June 29, 2021. The transaction has been approved by the board.분석 기사 • Mar 23With EPS Growth And More, Amicogen (KOSDAQ:092040) Is InterestingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩36,300, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 7.7% over the past three years.분석 기사 • Mar 05Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?Amicogen, Inc. ( KOSDAQ:092040 ) shareholders might be concerned after seeing the share price drop 14% in the last...Is New 90 Day High Low • Feb 24New 90-day low: ₩29,700The company is down 11% from its price of ₩33,400 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.분석 기사 • Feb 15Is Amicogen (KOSDAQ:092040) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 08New 90-day low: ₩31,700The company is down 5.0% from its price of ₩33,300 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.분석 기사 • Jan 31What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?Every investor in Amicogen, Inc. ( KOSDAQ:092040 ) should be aware of the most powerful shareholder groups...분석 기사 • Jan 14Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?Amicogen (KOSDAQ:092040) has had a rough three months with its share price down 5.7%. However, stock prices are usually...분석 기사 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩38,400, the stock is trading at a trailing P/E ratio of 22.1x, up from the previous P/E ratio of 19.2x. This compares to an average P/E of 56x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 68%.분석 기사 • Dec 15Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Nov 30Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?While Amicogen, Inc. (KOSDAQ:092040) shareholders are probably generally happy, the stock hasn't had particularly good...주주 수익률A092040KR BiotechsKR 시장7D0.9%-7.9%-8.2%1Y-42.5%23.0%159.6%전체 주주 수익률 보기수익률 대 산업: A092040은 지난 1년 동안 23%의 수익을 기록한 KR Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: A092040은 지난 1년 동안 159.6%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A092040's price volatile compared to industry and market?A092040 volatilityA092040 Average Weekly Movement13.6%Biotechs Industry Average Movement11.3%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%안정적인 주가: A092040의 주가는 지난 3개월 동안 KR 시장보다 변동성이 컸습니다.시간에 따른 변동성: A092040의 주간 변동성(14%)은 지난 1년 동안 안정적이었지만 KR 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트2000n/an/awww.amicogen.com아미코젠은 국내 및 해외에서 산업 생명공학 기업으로 운영되고 있습니다. 효소 및 신소재 개발, 생산, 판매, 식품 관련 첨가제 및 건강기능식품을 생산하고 있습니다. 제약용 단백질 정제용 바이오 의약품 소재와 수지, 건강 및 미용 제품을 제조 및 판매합니다.더 보기Amicogen, Inc. 기초 지표 요약Amicogen의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A092040 기초 통계시가총액₩132.45b순이익 (TTM)-₩29.96b매출 (TTM)₩41.98b2.9x주가매출비율(P/S)-4.0x주가수익비율(P/E)A092040는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A092040 손익계산서 (TTM)매출₩41.98b매출원가₩36.69b총이익₩5.29b기타 비용₩35.25b순이익-₩29.96b최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-425.24총이익률12.60%순이익률-71.36%부채/자본 비율87.4%A092040의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 10:20종가2026/05/21 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Amicogen, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관So-Eun ChoiLS Securities Co., Ltd.
공시 • Mar 11Amicogen, Inc., Annual General Meeting, Mar 31, 2026Amicogen, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea
New Risk • Feb 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (₩87.7b market cap, or US$61.5m).
New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩69.6b market cap, or US$48.2m).
공시 • Feb 10Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion.Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 1164
분석 기사 • Dec 22Investors Don't See Light At End Of Amicogen, Inc.'s (KOSDAQ:092040) Tunnel And Push Stock Down 33%Unfortunately for some shareholders, the Amicogen, Inc. ( KOSDAQ:092040 ) share price has dived 33% in the last thirty...
New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 52% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩108.0b market cap, or US$73.0m).
공시 • Mar 11Amicogen, Inc., Annual General Meeting, Mar 31, 2026Amicogen, Inc., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea
New Risk • Feb 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (₩87.7b market cap, or US$61.5m).
New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩69.6b market cap, or US$48.2m).
공시 • Feb 10Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion.Amicogen, Inc. has completed a Follow-on Equity Offering in the amount of KRW 17.373135 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 1164
분석 기사 • Dec 22Investors Don't See Light At End Of Amicogen, Inc.'s (KOSDAQ:092040) Tunnel And Push Stock Down 33%Unfortunately for some shareholders, the Amicogen, Inc. ( KOSDAQ:092040 ) share price has dived 33% in the last thirty...
New Risk • Dec 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 52% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (₩108.0b market cap, or US$73.0m).
공시 • Dec 20Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion.Amicogen, Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.000002 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,925,374 Price\Range: KRW 2010
New Risk • Dec 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩143.8b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩143.8b market cap, or US$97.9m).
New Risk • Nov 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩44b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩44b free cash flow). Earnings have declined by 52% per year over the past 5 years.
분석 기사 • Sep 08The Market Doesn't Like What It Sees From Amicogen, Inc.'s (KOSDAQ:092040) Revenues YetWith a price-to-sales (or "P/S") ratio of 1.8x Amicogen, Inc. ( KOSDAQ:092040 ) may be sending very bullish signals at...
공시 • Aug 12Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.On August 11, 2025, Amicogen, Inc. closed the transaction.
New Risk • Jul 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩25b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 46% per year over the past 5 years.
분석 기사 • May 23Amicogen, Inc.'s (KOSDAQ:092040) Share Price Is Matching Sentiment Around Its RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 1.3x Amicogen, Inc. ( KOSDAQ:092040 ) is definitely a...
Reported Earnings • Mar 25Full year 2024 earnings released: ₩961 loss per share (vs ₩584 loss in FY 2023)Full year 2024 results: ₩961 loss per share (further deteriorated from ₩584 loss in FY 2023). Revenue: ₩173.6b (up 8.6% from FY 2023). Net loss: ₩52.8b (loss widened 127% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings.
공시 • Mar 12Amicogen, Inc., Annual General Meeting, Mar 27, 2025Amicogen, Inc., Annual General Meeting, Mar 27, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 33, yeongudanji-ro 55beon-gil, yeonsu-gu, incheon South Korea
분석 기사 • Feb 17Is Amicogen (KOSDAQ:092040) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Jan 08Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 35%Amicogen, Inc. ( KOSDAQ:092040 ) shareholders are no doubt pleased to see that the share price has bounced 35% in the...
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).
공시 • Dec 12An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion.An undisclosed buyer agreed to acquire an unknown stake in Amicogen (China) Biopharm Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 54.7 billion on December 10, 2024. After completion of this ransaction, Amicogen, Inc. will hold 14.36% stake in Amicogen (China) Biopharm. Amicogen (China) Biopharm reported total assets of KRW 210.359 billion, total debt of KRW 95.656 billion, sales of KRW 84.911 billion and net income of KRW 8.074 billion as at September 30, 2024. The expected completion of the transaction is December 30, 2024.
New Risk • Dec 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 3.7% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (3.7% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (40% increase in shares outstanding).
New Risk • Dec 07New minor risk - Financial data availabilityLess than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (40% increase in shares outstanding).
공시 • Nov 23Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040).Enzynomics Co., Ltd. agreed to acquire 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) for KRW 5.6 billion on November 15, 2024. A cash consideration of KRW 5.6 billion will be paid by Enzynomics for 2,360,714 shares. For the period ending December 31, 2023, SKINMED Co., Ltd. reported total revenue of KRW 6.07 billion and net loss of KRW 1.04 billion. As of December 31, 2023, SKINMED Co., Ltd. reported total debt of KRW 4.96 billion, total assets of KRW 11.22 billion and total common equity of KRW 6.26 billion. Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc. (KOSDAQ:A092040) on November 19, 2024.
분석 기사 • Nov 11Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share PriceAmicogen, Inc.'s ( KOSDAQ:092040 ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a strong buy right...
공시 • Oct 30+ 1 more updateAmicogen, Inc. announced that it has received KRW 4 billion in funding from Kiwoom Securities Co., Ltd.On October 29, 2024 Amicogen, Inc. closed the transaction.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (40% increase in shares outstanding).
분석 기사 • Jun 27Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% PoundingTo the annoyance of some shareholders, Amicogen, Inc. ( KOSDAQ:092040 ) shares are down a considerable 27% in the last...
분석 기사 • Jun 19Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
분석 기사 • Mar 21Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%Amicogen, Inc. ( KOSDAQ:092040 ) shares have had a really impressive month, gaining 39% after a shaky period...
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).
New Risk • Dec 28New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 39% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Earnings have declined by 48% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (39% increase in shares outstanding).
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 44% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.6% average weekly change).
공시 • Jul 19+ 1 more updateAmicogen, Inc. announced that it expects to receive KRW 40 billion in fundingAmicogen, Inc. announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 40,000,000,000 on July 18, 2022. The bonds will mature on July 20, 2027. The bonds are convertible into 1,622,520 common shares at a price of KRW 24,653 per share. The conversion period is from July 20, 2023 to June 20, 2027. The payment date is July 20, 2022. The transaction has been approved by the board of directors.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩24,850, the stock trades at a trailing P/E ratio of 14.6x. Average trailing P/E is 33x in the Biotechs industry in South Korea. Total loss to shareholders of 34% over the past three years.
공시 • Sep 03Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AGOn September 2, 2021, Amicogen, Inc. closed the transaction.
공시 • Jul 23Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion.Amicogen, Inc. (KOSDAQ:A092040) agreed to acquire a 30% stake in BIFIDO Co., Ltd (KOSDAQ:A238200) from a group of shareholders for KRW 60.1 billion on July 21, 2021. Under the term, Amicogen will acquire 2.45 million shares of BIFIDO at KRW 24,500 per shares. Amicogen will pay 20% of the consideration amounting to KRW 12.02 billion on July 21, 2021 as the down payment or first payment, second payment or the interim payment which is 30% of the consideration amounting to KRW 18.04 billion will be paid on August 20, 2021 and the balance which is 50% of the consideration amounting to KRW 30.06 billion will be paid on October 20, 2021. Post completion, Amicogen will hold 30% stake in BIFIDO. The transaction was resolved by the board of directors of Amicogen on July 21, 2021. The transaction is expected to close on October 21, 2021.
공시 • Jul 15Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AGAmicogen, Inc. announced a private placement of 532,198 shares at a price of KRW 41,850 per share for gross proceeds of KRW 22,272,486,300 on July 14, 2021. The transaction will include participation from Lysando AG. The transaction is expected to close on August 20, 2021. The securities to be issued will have a hold period of 1 year. The transaction was approved by the board of directors of the company. The company will received funding through third party allocation.
공시 • Jul 01Amicogen, Inc. announced that it has received KRW 50 billion in fundingOn June 29, 2021, Amicogen, Inc. closed the transaction.
공시 • Jun 24Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding from Samsung Securities Co., Ltd. and other investorsAmicogen, Inc. (KOSDAQ:A092040) announced a private placement of series 1 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 50,000,000,000 on June 23, 2021. The transaction will include participation from Samsung Securities Co., Ltd. (KOSE:A016360) for KRW 46,000,000,000, and Small and Medium Business Banks for the rest. The bonds will mature on June 28, 2026. The bonds are convertible into 1,203,311 common shares at a price of KRW 41,552 per share. The conversion period is from June 29, 2022 to May 29, 2026. The payment date is June 29, 2021. The transaction has been approved by the board.
분석 기사 • Mar 23With EPS Growth And More, Amicogen (KOSDAQ:092040) Is InterestingFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩36,300, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 54x in the Biotechs industry in South Korea. Total returns to shareholders of 7.7% over the past three years.
분석 기사 • Mar 05Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?Amicogen, Inc. ( KOSDAQ:092040 ) shareholders might be concerned after seeing the share price drop 14% in the last...
Is New 90 Day High Low • Feb 24New 90-day low: ₩29,700The company is down 11% from its price of ₩33,400 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period.
분석 기사 • Feb 15Is Amicogen (KOSDAQ:092040) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 08New 90-day low: ₩31,700The company is down 5.0% from its price of ₩33,300 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 7.0% over the same period.
분석 기사 • Jan 31What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?Every investor in Amicogen, Inc. ( KOSDAQ:092040 ) should be aware of the most powerful shareholder groups...
분석 기사 • Jan 14Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?Amicogen (KOSDAQ:092040) has had a rough three months with its share price down 5.7%. However, stock prices are usually...
분석 기사 • Dec 30Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?Statistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₩38,400, the stock is trading at a trailing P/E ratio of 22.1x, up from the previous P/E ratio of 19.2x. This compares to an average P/E of 56x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 68%.
분석 기사 • Dec 15Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
분석 기사 • Nov 30Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?While Amicogen, Inc. (KOSDAQ:092040) shareholders are probably generally happy, the stock hasn't had particularly good...
